April 23rd 2024
ME-344 and bevacizumab can now have an additional 20 patients enrolled on the phase 1b trial for relapsed metastatic colorectal cancer.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
2024 Miami International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Scoring Algorithms Demonstrate Utility in Screening for Optimal Treatment for HER2+ mCRC
January 23rd 2023Findings from the phase 2 MOUNTAINEER trial indicate that HER2 scoring algorithms may help in identifying which patients are suitable to receive tucatinib plus trastuzumab for metastatic colorectal cancer.
ctDNA May Be Ideal Biomarker for Early Response Assessment in Advanced Colorectal Cancer
January 22nd 2023Molecular responders by G360 response algorithm with advanced colorectal cancer appear to have significantly lengthened time on treatment and overall survival with all regimens vs patients who did not respond.
FDA Grants Breakthrough Therapy Designation to Adagrasib/Cetuximab for KRAS G12C+ CRC
December 22nd 2022The FDA granted breakthrough therapy designation to adagrasib plus cetuximab for patients with KRAS G12C–mutated advanced colorectal cancer based on findings from the phase 1b cohort of the KRYSTAL-1 trial.
Alberto Calvo-García, PharmG, and colleagues analyzed routinely-collected data to assess regorafenib in metastatic colorectal cancer.
FDA Approves New Dosing Regimens, Indications for Capecitabine Across Multiple Cancer Types
December 15th 2022The FDA’s approval of new indications and dosing regimens of capecitabine across several cancer types, including breast cancer and colon cancer, marks the first drug to receive an update under the agency’s Project Renewal program.